期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向性药物赫赛汀治疗乳腺癌临床应用新进展 被引量：4

New clinical researches on molecular target drug for--Herceptin breast cancer therapy
下载PDF
导出
摘要 赫赛汀 (Herceptin)是乳腺癌治疗领域的第 1个分子靶向性药物。
作者 王涛 江泽飞 宋三泰
机构地区 军事医学科学院
出处 《国外医学（肿瘤学分册）》 2003年第2期139-142,共4页 Foreign Medical Sciences (Cancer Section)
关键词 乳腺癌 赫赛汀 分子靶向性药物 联合化疗 长春瑞宾 紫杉醇 紫杉特尔 蒽环类药物 卡培他滨
分类号 R737.9 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer [J]. Science,1989,244(4905) : 707-712.
  • 2Lohrisch C, Piccart M. HER-2/neu as a predictive factor in breast cancer [J]. Clin Breast Cancer, 2001, 2(2): 129-135.
  • 3Leyland Jones B. Trastuzumab: hopes and realities [J]. Lancet Oncol, 2002,3(3): 137-144.
  • 4Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [J]. Oncogene, 1997,15(5) : 537-547.
  • 5Burstein HJ, Kuter I, Campos SM, Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer [J]. J Clin Oncol, 2001, 19(10): 2722-2730.
  • 6Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER-2 ( + ) metastatic breast cancer [J]. Oncologist, 2002,7(5):410-417.
  • 7Thossen C. Trials of new combination of Herceptin in metastatic breast cancer [J]. Aaticancer Drugs, 2001, 12(Suppl 4): 19-25.
  • 8Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification [ J ]. J Clin Oncol, 2001, 19(10): 2587-2595.
  • 9Bell R. Ongoing trials with trastuzumab in metastatic breast cancer[J]. Ann Oncol, 2001,12 (Suppl 1): 69-73.
  • 10Pegram MD.Docetaxel and herceptin:fourdation for future strategies[J].Oncologist,2001,6 (Suppl 5):22-25.

同被引文献49

  • 1江泽飞,王涛,姚开泰.针对HER-2的乳腺癌分子靶向药物赫赛汀治疗新动向[J].中国实用内科杂志,2005,25(8):681-683. 被引量：9
  • 2王莉萍,沈坤炜,沈镇宙.赫赛汀在乳腺癌新辅助治疗与辅助治疗中的新进展[J].中华肿瘤杂志,2006,28(4):241-243. 被引量：26
  • 3Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med,2001,344(11),783-792.
  • 4Forbes JF, Kennedy J, Pienkowski T, et al. BCIRG 007: randomized phase Ⅲ trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC) [J]. J Clin Oncol, 2006,24(Suppl) : 516.
  • 5Minckwitz CV, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumah treatment: The TBP phase Ⅲ study (GBG 26/BIG 3-05)[J]. J Clin Oncol, 2008,26 (Suppl), 1025.
  • 6Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer [J]. N Engl J Med, 2005,353(16):1659-1672.
  • 7Romond EH, Perez EA. Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer [J].N Engl J Med,2005, 353 (16):1673-1684.
  • 8Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2- positive early breast cancer [J]. Oncologist, 2006,11 (Suppl 1) :4-12.
  • 9Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer [J]. Clin Adv Hematol Oncol, 2006,4 (suppl 1) : 4 - 9.
  • 10Geyer CE,Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J]. N Engl J Med,2006,355(26),2733-2743.

引证文献4

二级引证文献50

国外医学（肿瘤学分册）
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部